Explore All 789 Divestiture Life Science Deals - Search the Database Free
M&A Deal Summary |
|
|---|---|
| Date | May 24, 2021 |
| Target | Myriad RBM |
| Sector | Life Science |
| Buyer(s) | Q² Solutions |
| Sellers(s) | Myriad |
| Deal Type | Divestiture |
FILTER BY
| Category | Company |
|---|---|
| Founded | 2015 |
| Sector | Life Science |
Q² Solutions is a global clinical trial laboratory services organization that helps biopharmaceutical, medical device, and diagnostics customers improve human health through innovation that transforms science and data into actionable medical insights. Q² Solutions is a quality-driven, responsive partner with strong global experience and deep scientific and medical expertise. Q² Solutions was formed in 2015 and is based in Morrisville, North Carolina.
| Deal Context for Buyer | # |
|---|---|
| Overall | 1 of 2 |
| Sector: Life Science | 1 of 2 |
| Type: Divestiture | 1 of 1 |
| State: Texas | 1 of 1 |
| Country: United States | 1 of 1 |
| Year: 2021 | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-01-10 |
Nexelis
Laval, Quebec, Canada Nexelis is an immunology-centric CRO specialized in preclinical models and clinical assay development in single and multiplex formats and sample analysis for low-, mid- and large-scale clinical testing. the company's team of scientists and technology platforms have been instrumental in the development, qualification, and validation of assays supporting FDA filings of over 100 new molecular entities, including blockbuster biologics such as vaccines and complex large molecules. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1991 |
| Sector | Life Science |
| Employees | 2,700 |
| Revenue | 838M USD (2024) |
Myriad is a molecular diagnostic company that discovers and commercialize a transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad was founded in 1991 and is based in Salt Lake City, Utah.
| Deal Context for Seller | # |
|---|---|
| Overall | 4 of 4 |
| Sector: Life Science | 2 of 2 |
| Type: Divestiture | 4 of 4 |
| State: Texas | 1 of 1 |
| Country: United States | 4 of 4 |
| Year: 2021 | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-05-03 |
Myriad Autoimmune s Vectra Testing Business
Salt Lake City, Utah, United States Myriad Autoimmune's Vectra Testing Business is a non-invasive, blood-based test that analyzes 12 biomarkers to measure RA disease activity. It combines those measures to generate an easy-to-understand score, which indicates the severity of RA inflammation and how well current treatments are working. It also can predict potential, future joint damage. This enables the 5,000 practicing rheumatologists in the U.S. to provide targeted treatment and adjust existing treatments to better manage RA symptoms. |
Sell | $150M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-05-07 |
Myriad Genetics - EndoPredict Business
Salt Lake City, Utah, United States Myriad Genetics' EndoPredict Business offers a comprehensive suite of precision medicine tools for breast, prostate, ovarian, pancreatic, endometrial, and colon cancer. Myriad Genetics' EndoPredict Business is based in Salt Lake City, Utah. |
Buy | - |
